PharmaLive: Senesco Technologies to Present at BioPharm America 2008
September 3rd, 2008 | by admin |
NEW BRUNSWICK, N.J., September 03, 2008 /PRNewswire-FirstCall/ — Senesco Technologies, Inc. ("Senesco" or the "Company") today announced that the Company will be presenting at BioPharm America(TM) 2008. The conference is being held at the Grand Hyatt Hotel Atlanta in Buckhead, GA from September 9-10, 2008. Bruce Galton, Chief Executive Officer of Senesco, will deliver the Company’s corporate presentation on Tuesday, September 9, at 4:15 p.m.
The objective of BioPharm America(TM) 2008 is to provide executives from pharmaceutical and biotechnology companies the opportunity to meet face-to-face and discuss potential strategic relationships and the latest industry trends. The event is expected to draw over 400 top level business development executives from approximately 65 companies across the pharmaceutical and biotechnology industries.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners’ products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company’s license agreements; the successful conversion of the Company’s letter of intent into a license agreement; the acceptance by the market of the Company’s products; success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward- looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
CONTACT: Bruce Galton, Chief Executive Officer, Senesco Technologies,Inc., +1-732-296-8400, ; or Investor Relations, BrianRitchie of FD for Senesco Technologies, Inc., +1-212-850-5600, bgalton@senesco.com brian.ritchie@fd.com
Ticker Symbol: (AMEX:SNT)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Stumble it!
